Study of Remternetug for Early Onset Alzheimer's Disease
This study is looking for people aged 18 and older who are at risk for, or have, a type of early onset Alzheimer's disease caused by a genetic mutation. It aims to see if Remternetug can prevent or slow the buildup of amyloid beta (Aβ) in the brain, which is a hallmark of Alzheimer's. You would receive Remternetug or a placebo (an inactive substance) as an injection under the skin every 12 weeks. The researchers will measure changes in Aβ levels and other markers related to Alzheimer's disease. The goal is to understand if this treatment can help slow down the disease's progression. The study is currently recruiting 280 participants.
- Study design
- This is an interventional study with 280 planned participants. It compares Remternetug to a matching placebo.
- What's involved
- You would undergo clinical assessments, cognitive testing, MRI and amyloid imaging, and analysis of cerebrospinal fluid (CSF) over a period of at least 208 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study evaluates effects at Week 208 for both stages of the trial.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
At a glance
Conditions
Where it's being run
37 sites across 35 statesStudy leadership
- Eric M McDade, DO · STUDY_DIRECTOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Stage 1: Evaluate the ability of study drug to prevent or slow the rate of Aβ accumulation compared with placebo in participants with mutations that cause DIADBaseline and Week 208
Defined in each drug-specific appendix; will be an assessment of biomarkers of early-stage disease (e.g., amyloid PET, soluble amyloid, soluble phospho-tau) compared with baseline in each treatment group
- Stage 2: Evaluate the effect of anti-amyloid treatment on downstream biomarkers of ADStage 2 Week 208
If applicable, will be defined in each drug-specific appendix, and will be an assessment of the change in progression of biomarkers representing tau, neurodegenerative, and inflammatory pathobiological events in the disease cascade for temporally different periods of the pre-symptomatic phases of the disease.